BioSpace News Archive

Catalyst Biosciences, Inc., a biopharmaceutical company developing novel subcutaneous therapies for hemophilia and other bleeding disorders, announced completion of dosing and the 30-day follow-up period for its Phase 2b trial of SQ dalcinonacog alfa.

Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled

IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Doris Engibous to its board of directors effective April 20, 2020. The Company will also nominate Ms. Engibous for re-election to the board at its 2020 Annual Meeting of Stockholders. “I am delighted to welcome Doris to our board of directors,” said

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian Pereira, M.D. and Shawn Tomasello, M.B.A. as Executive Chairman and Independent Board Member, respectively. “On behalf of the Board, I am pleased to welcome Brian and Shawn, and look forward to collaborating with them as we guide Abeona to success,” said Steven H. Rouhandeh, former Executive Chairman and

Allterum Therapeutics, Inc. , a Fannin Innovation Studio company, has closed on a $2.9 million Product Development award by the Cancer Research and Prevention Institute of Texas (CPRIT) to support preclinical development of its 4A10 antibody therapy for the treatment of pediatric patients suffering from T-cell acute lymphoblastic le

Acquist Therapeutics, Inc ., a biopharmaceutical company committed to discovery of new treatments for people with inflammatory diseases, today announced that the Company received a fourth patent from the U.S. Patent Office that cove

Athersys, Inc. will release its first quarter 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, May 7, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin ® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, today announced that the company will present data from its first in human study of PEN-866 at the 2020 American Association for Cancer Resear

Proven executive with clinical operations expertise to guide Company’s clinical programs with gene therapies

Myovant Sciences, a healthcare company focused on redefining care for women’s health and prostate cancer, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for once-daily, oral relugolix for the treatment of men with advanced prostate cancer.